文献速递免疫规划

采用计算机断层扫描成像比较两种多组分猫疫苗(含佐剂1 mL与无佐剂减量0.5 mL)的局部安全性

Comparison of the local safety of two multi-component feline vaccines, adjuvanted (1 mL) versus non-adjuvanted at reduced volume (0.5 mL), using computed tomography imaging.
PubMed 文献 · Vaccine · 2023-06-23

2020年欧洲注册了0.5 mL无佐剂PUREVAX® RCP FeLV猫疫苗,本研究通过临床检查、组织病理学和计算机断层扫描(CT)评估其接种后3个月内局部反应,并与含佐剂LEUCOFELIGEN® FeLV/RCP 1.0 mL疫苗比较;无佐剂减量疫苗局部炎症反应更少、更轻、持续时间更短,CT扫描是合适的非侵入性随访方法。

要点

  • 无佐剂减量疫苗组注射部位肿胀反应较含佐剂疫苗组更少、更轻且持续时间更短。
  • 含佐剂疫苗组D7和D21所有猫CT可测炎性区域,无佐剂组仅D7在20%猫中检出。
  • CT扫描结果与临床评估和组织病理学在D7和D21一致,适用于注射部位反应随访。

核心结论

  • 通过不同方法证实PUREVAX® RCP FeLV 0.5 mL具有良好安全性,且符合现行疫苗接种指南,因其炎症反应更少、无佐剂、减量注射,提高了在推荐部位(如腿部)接种的便利性。
  • CT扫描被证明是实验性随访注射部位反应的合适非侵入性方法,其结果与D7和D21的临床评估及组织病理学一致。

研究设计与样本

  • 研究比较了PUREVAX® RCP FeLV 0.5 mL无佐剂减量疫苗与LEUCOFELIGEN® FeLV/RCP 1.0 mL含佐剂疫苗皮下注射后3个月内局部反应的过程。
  • 采用经典方法(临床检查、组织病理学)评估局部安全性,并评估CT作为替代非侵入性方法的适用性。

主要发现

  • 注射部位反应主要为肿胀反应,在含佐剂疫苗组更频繁、更明显且持续时间更长。
  • 显微镜下,含佐剂疫苗组在注射后D7和D21观察到中至重度炎症反应,D84时仍存在;而无佐剂疫苗组仅在D7和D21观察到轻度炎症病变。
  • 含佐剂疫苗组所有猫在D7和D21经CT扫描可测到炎性区域,而无佐剂疫苗组仅在D7且仅在20%的猫中检出。
  • 除频率更高外,含佐剂疫苗组在D7的平均炎性体积几乎大300倍。

临床怎么用

  • 作者认为,PUREVAX® RCP FeLV 0.5 mL因炎症反应更少、无佐剂且减量注射,符合现行疫苗接种指南,并提高了在推荐部位(如腿部)接种的便利性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2020, a new 0.5 mL presentation of PUREVAX® RCP FeLV was registered and introduced in Europe. The objectives of this study were to investigate the local safety of this non-adjuvanted vaccine at reduced volume by classical methods (clinical examination, histopathology) and to evaluate the suitability of an alternative non-invasive methodology, the computed tomography (CT). For this purpose, the course of local reactions was assessed for 3 months after subcutaneous injection of PUREVAX® RCP FeLV 0.5 mL and compared to an adjuvanted vaccine, LEUCOFELIGEN® FeLV/RCP 1.0 mL. Injection site reactions consisted mainly of swelling reactions, which were more frequent, more pronounced and long-lasting in the adjuvanted vaccine group. Microscopically, in this group, moderate to severe inflammatory reactions were observed on day 7 (D7) and D21 post-injection and still present on D84, while mild inflammatory lesions were observed in the non-adjuvanted vaccine group only on D7 and D21. With the adjuvanted vaccine, inflamed areas were measurable by CT scan in all cats on D7 and D21, whereas they were detected only on D7 and only in 20 % of cats from the non-adjuvanted vaccine group. Besides the higher frequency, the mean inflamed volume was nearly 300 times larger in adjuvanted vaccine group on D7. Using different methodologies, the favorable safety profile of PUREVAX® RCP FeLV 0.5 mL was confirmed. Furthermore, the vaccine is aligned with current vaccination guidelines by inducing less inflammatory reactions, being adjuvant-free and injectable under a reduced volume, thus improving the convenience of administration in recommended sites (eg, legs). CT scan proved to be a suitable non-invasive method for the experimental follow-up of injection site reactions, yielding results consistent with clinical assessment and histopathology on D7 and D21. CT scan substantiated large differences between the investigated vaccines with a more prominent inflammatory reaction after injection of an adjuvanted vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haist V, Bellebeau-Barbier F, Montange C, et al. Comparison of the local safety of two multi-component feline vaccines, adjuvanted (1 mL) versus non-adjuvanted at reduced volume (0.5 mL), using computed tomography imaging. Vaccine. 2023. PMID: 37355451. doi:10.1016/j.vaccine.2023.06.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。